miércoles, 20 de agosto de 2014

El TOP 10 de los fármacos más consultados por los profesionales sanitarios en Vademecum

El sitio web de Vademecum ha hecho un análisis de los fármacos más consultados por los profesionales de la salud en el primer semestre del año y ha descubierto que el TOP 10 está integrado por: Cialis®, Clexane®, Enantyum®, Urbason®, Hidroxil®-B12-B6-B1, Apiretal®, Monurol®, Nolotil®, Augmentine® y Yasmin®. 

El fármaco Cialis, del laboratorio Lilly, ha sido el fármaco más consultado en vademecum.es en el periodo analizado, con un total de 71.888 páginas vistas de su ficha técnica. Le sigue, en segunda posición, Clexane, de la compañía Sanofi que, con 48.665 páginas vistas, se posiciona en el segundo escalafón de fármacos más visitados en vademecum.es hasta la fecha; y en tercer lugar se encuentra Enantyum, de Menarini, que acumula 45.194 páginas vistas de los profesionales sanitarios en lo que va de año. 

Por otro lado, las compañías farmacéuticas que más están captando la atención de los profesionales sanitarios en vademecum.es en estos meses son Sanofi (491.190 PV’s), Pfizer (422.496 PV’s), Bayer (418.317 PV’s), Almirall (331.917 PV’s) y Novartis (285.036 PV’s), respectivamente. 

En lo que a principios activos se refiere, los más consultados en estos seis primeros meses han sido: paracetamol (con 152.374 páginas vistas), ibuprofeno (con 136.001 páginas vistas), Drospirenona Etinilestradiol (120.090 PV’s), Acetilcisteína (91.332 PV’s) y Omeprazol (82.195 PV’s). 

De igual manera, si analizamos las búsquedas en la web de Vademecum por indicación terapéutica en estos meses de enero a junio, encontramos que los términos más buscados en este apartado son los de hemorroides, aftas bucales y picaduras y mordeduras de insectos, con un acumulado de 15.932, 4.298 y 3.798 páginas vistas. 

Asimismo, si establecemos un ranking atendiendo a la clasificación ATC de los medicamentos, observamos que la categoría con mayor número de páginas vistas en vademecum.es en lo que va de año es la de Sistema Nervioso, con 3.432.093 páginas vistas (PV’s), seguida de la categoría Tracto Alimentario y Metabolismo (2.345.112 PV’s) y de Antiinfecciosos para Uso Sistémico (2.007.483 páginas vistas). (Más

martes, 19 de agosto de 2014

Walgreens alía Alliance Boots

La mayor cadena farmacéutica de Estados Unidos, Walgreens, ha llegado a un acuerdo para adquirir el 55% que no poseía del grupo farmacéutico y de cosmética británico Alliance Boots por alrededor de 15.260 millones de dólares (11,431 millones de euros) en efectivo y acciones, según informó la compañía.(Más)

domingo, 17 de agosto de 2014

Al "filo" del alprostadil(o) en crema: VITAROS

Men in the UK suffering from erectile dysfunction (ED) are the first in the world to get access to the first cream on the market for treating the condition.

...patients aged over 18 will be able to get a prescription for Vitaros (topical alprostadil cream) - developed by Apricus Bioscienes but marketed in the UK by Takeda - offering another treatment option to the 2.3 million in the country with ED. 

The cream comes in a single use, disposable applicator and can produce an erection within five-30 minutes, providing an alternative, non-invasive option for those men considering alprostadil treatment. Approval in Europe came in June last year, on the back of Phase III clinical trial data showing that almost 40% of men using 300mcg of topical alprostadil experienced a clinically significant improvement in their erection function compared to 21% of men using placebo. In a long-term open label study, 90% of men using Vitaros for six months considered their erection improved compared to at the beginning of the trial, Takeda noted. Professor Raj Persad, Consultant Urologist and Andrologist, The Bristol Urological Institute, said Vitaros is "an important step forward in the treatment of ED", and one that might help treat more patients with the condition. "As Vitaros is easy to use and only needs verbal instruction around the application of the cream, it could potentially be prescribed in primary care, giving GPs and practice nurses the ability to treat more men with ED," he noted.

viernes, 15 de agosto de 2014

Ratón de biblioteca: The Tylenol mafia

On September 29, 1982, seven people in Chicago died after taking Extra Strength Tylenol capsules laced with cyanide. Officials have long cited the scarcity of physical evidence and apparent lack of motive to explain why they never solved the Tylenol murders. However, new revelations and information not previously disclosed tell a very different story of a crime that should have been solved. 

 In a story both fascinating and dramatic in its warnings, The Tylenol Mafia rips away the facade of an investigation that J&J CEO James Burke labeled "A demonstration without parallel of government and business working with the news media to help protect the public." This gripping, meticulously documented expose' unearths the troubling details of an investigation corrupted by well-connected corporate executives and politically motivated government officials who simply buried the truth inside a shadow legal system inaccessible to everyday Americans.

jueves, 14 de agosto de 2014

China sentences GSK-linked investigators to prison

China sentenced a British corporate investigator to 2-1/2 years in prison on Friday for illegally obtaining private records of Chinese citizens and selling the information on to clients including drugmaker GlaxoSmithKline Plc. 

Peter Humphrey and his American wife, Yu Yingzeng, who ran risk consultancy ChinaWhys, were tried in a Shanghai court. They said they were unaware such acts were criminal. 

In a late evening verdict, the court said it found Humphrey and Yu guilty and handed Yu a slightly more lenient sentence of two years in jail. Humphrey was fined 200,000 yuan (19,375.26 pound), while Yu was fined 150,000 yuan. 

According to a statement read out by a court official at a press conference, Humphrey will be deported. The court gave no further details about that aspect of the judgment. 

"The two defendants illegally collected Chinese citizens' information over a long period of time and on many occasions. They collected a large amount of data and had also used illegal means, including investigative methods," said Tang Liming, vice-president of Shanghai No.1 People's Intermediate Court. (Más)

Ver también:

2001 "A GSK China Odyssey..." / El inicio de la "saga_cidad".

miércoles, 13 de agosto de 2014

PFIZER: Rapamune herencia "caida" en desgracia...desde la Isla de Pascua

Rapa Nui caido Isla Pascua Chile

Pfizer settles off-label Rapamune case for $35M 

Pfizer will pay $35 million to settle with 41 state attorneys general for alleged off-label marketing and promotion of immunosuppressive drug Rapamune by legacy company Wyeth, New York's attorney general, Eric Schneiderman, said today. Pfizer acquired Wyeth in 2009 for $68 billion. 

In the settlement, Schneiderman said Wyeth allegedly promoted the drug for use in liver, heart and drug transplants when the drug was only approved for use after kidney transplants. “Patients and consumers need to have confidence in the truthfulness of claims made to them by medical providers without having to worry about drug companies manipulating the doctor-patient relationship,” he stated. 

Rapamune* (sirolimus) was originally approved by the FDA in September 1999 to help patients better tolerate kidney transplants and lessen the chance of rejection. Neither drugmaker has admitted to liability or wrong-doing. 

The complaint further alleged that Wyeth violated consumer protection laws by misrepresenting the drug's uses and benefits through promotional talks by Wyeth-retained doctors and misleading presentations of data as well as funding of studies at hospitals and transplant centers designed to encourage off-label use of Rapamune

The settlement follows last year's $490.9 million agreement between Pfizer and the Department of Justice to resolve criminal and civil liability over Rapamune marketing. Of that sum, $257.4 million went to the federal government and states to resolve prosecutors' civil claims that Wyeth allegedly violated the False Claims Act by promoting the drug for unapproved uses, and that those uses were therefore not covered by Medicare, Medicaid or other federal programs. 

In that same 2013 settlement, Pfizer also paid out $233.5 million for a criminal fine and forfeiture under a plea agreement with US District Court in Oklahoma City after Wyeth pled guilty to a FDCA (Federal Food, Drug and Cosmetic Act) misbranding violation. The deal came after information which alleged that Wyeth trained its national Rapamune sales force to promote the use of the drug in non-renal transplant patients and that the sales force was later encouraged to target all transplant populations to increase sales. 

Stuart Delery—the acting assistant attorney general for the Justice Department's Civil Division at the time—stated: “Wyeth trained its sales force to promote Rapamune for off-label uses not approved by the FDA, including ex-renal uses, and even paid bonuses to incentivize those sales. This was a systemic, corporate effort to seek profit over safety.” (Ver)

(*)Uno de los fármacos más populares de los últimos años es la rapamicina. Con este nombre, Sirolimus, o el nombre comercial de Rapamune se emplea en la terapia post transplante, para prevenir la restenosis después de una angioplasia (traduzco: para que no se inflamen las arterias después de una operación) en la terapia contra el cáncer y en muchas otras. Curiosamente una molécula con tantas aplicaciones y tan efectiva tuvo unos orígenes modestos y muy remotos.

Wyeth homenaje Rapamicina/Isla Pascua
La historia empieza en la isla de Pascua, donde unos científicos de la empresa Wyeth pasaban las vacaciones. La empresa, experta en buscar antibióticos procedentes de hongos, pedía a todos sus empleados que recogieran muestras de suelo de los países que visitaban. En la tierra que recogieron se encontraron unas cepas del hongo Streptomyces hygroscopicus, del que se aisló una molécula de la familia de los policétidos macrocíclicos, a la que se le denominó rapamicina. El nombre proviene de la denominación que los antiguos navegantes proveniente de Tahití dieron a la isla de Pascua: Rapa Nui. Este compuesto interesó inicialmente por tener una actividad antifúngica, pero carente de valor práctico. Era muy caro y muy inestable. No obstante, la rapamicina no había dicho su última palabra. Se descubrió que era muy tóxica para los glóbulos blancos. En condiciones normales un compuesto que machaque al sistema inmune es un veneno, pero hay veces que conviene mantener a raya a este sistema. Básicamente: después de un transplante para prevenir un rechazo. Aquí es cuando empieza el éxito de la rapamicina como fármaco.(Ver)

Ver también:

RAPAMICINA: El elixir de la "eterna juventud" está en Isla de Pascua...